Skip to main content

$0.260 0.035 (15.56%)

High

$0.26

Low

$0.22

Trades

21

Turnover

$59,559

Volume

239,872
30 June 2023 at 4:10pm
Register to track UBI and receive email alerts.
Subject
UBI Ann: Appendix 3Y - Craig Coleman

UBI Ann: Universal Biosensors banks $25.2 million

UBI Ann: Appendix 2A Entitlement Offer

UBI Ann: Appendix 3G

UBI Ann: Results of Entitlement Offer

UBI Ann: Results of Special Meeting of Securityholders 23 May 2022

UBI Ann: Form 604 - Jencay Capital Pty Ltd

UBI Ann: Form 604 - JM Financial Group Ltd

UBI Ann: Fully Underwritten $20 million Entitlement Offer - Update

UBI Ann: Appendix 3Y - Graham McLean

UBI Ann: Appendix 3X - Graham McLean

UBI Ann: Appendix 2A

UBI Ann: Application of Foreign Ownership Restriction Facility

UBI Ann: Application for quotation of securities - UBI

UBI Ann: Notice of Meeting of Stockholders to be held on 23 May 2022

UBI Ann: Becoming a substantial holder

UBI Ann: Placement Cleansing Notice

UBI Ann: Q1 2022 Results

UBI Ann: March 2022 Quarterly Activity Report and Appendix 4C

UBI Ann: Notice of Meeting/Proxy Statement

UBI Ann: Appendix 2A

UBI Ann: Retail Entitlement Offer Booklet

UBI Ann: Update to Placement Timetable

UBI Ann: UBI successfully raises $6m via an Institutional Placement

UBI Ann: Update - Proposed issue of securities - UBI

UBI Ann: Clarification Regarding Entitlement Offer Timetable

UBI Ann: Notification to Ineligible Securityholders

UBI Ann: Notification to Eligible Securityholders

UBI Ann: Proposed issue of securities - UBI

UBI Ann: Proposed issue of securities - UBI

UBI Ann: Cleansing Notice

UBI Ann: UBI Investor Presentation - Capital Raising

UBI Ann: UBI - Capital Raising

UBI Ann: Tn Antigen Peter Mac Development Clinical Study Results

UBI Ann: Trading Halt

UBI Ann: Form 604 - JM Financial Group Ltd

UBI Ann: Clarification Announcement

UBI Ann: Graham McLean Appointed as Non-Executive Director

UBI Ann: FY2021 Corporate Governance Statement & Appendix 4G

UBI Ann: UBI Investor Presentation

UBI Ann: Regulatory Approval to sell Xprecia Prime in Europe

UBI Ann: Application for quotation of securities - UBI

UBI Ann: Appendix 4E and Annual Report on Form 10-K FY2021

UBI Ann: Notification of cessation of securities - UBI

UBI Ann: Application for quotation of securities - UBI

UBI Ann: December 2021 Appendix 4C and Quarterly Activity Report

UBI Ann: UBI launch Sentia Malic Acid Test globally

UBI Ann: UBI signs deal to commercialise SARS-CoV-2 N-Protein Test

UBI Ann: Application for quotation of securities - UBI

UBI Ann: Application for quotation of securities - UBI

Register to track UBI and receive email alerts.

Similar Companies

AT1
COH
CSX
CYC
EMV
IBX
IPD
MX1
RSH
SOM